BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swanson HI. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry? Drug Metab Dispos. 2015;43:1499-1504. [PMID: 26261284 DOI: 10.1124/dmd.115.065714] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 11.9] [Reference Citation Analysis]
Number Citing Articles
1 Stephens C, Lucena MI, Andrade RJ. Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 477-96. [DOI: 10.1007/978-1-4939-7677-5_23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Shi W, Hu Y, Ning Z, Xia F, Wu M, Hu YOO, Chen C, Prast-Nielsen S, Xu B. Alterations of gut microbiota in patients with active pulmonary tuberculosis in China: a pilot study. Int J Infect Dis 2021;111:313-21. [PMID: 34481968 DOI: 10.1016/j.ijid.2021.08.064] [Reference Citation Analysis]
3 Sadler NC, Webb-Robertson BM, Clauss TR, Pounds JG, Corley R, Wright AT. High-Fat Diets Alter the Modulatory Effects of Xenobiotics on Cytochrome P450 Activities. Chem Res Toxicol 2018;31:308-18. [PMID: 29688711 DOI: 10.1021/acs.chemrestox.8b00008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
4 Guo X, Yuan J, Song X, Wang X, Sun Q, Tian J, Li X, Ding M, Liu Y. Bacteria metabolites from Peganum harmala L. polysaccharides inhibits polyQ aggregation through proteasome-mediated protein degradation in C. elegans. Int J Biol Macromol 2020;161:681-91. [PMID: 32544588 DOI: 10.1016/j.ijbiomac.2020.06.091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhang C, Franklin CL, Ericsson AC. Consideration of Gut Microbiome in Murine Models of Diseases. Microorganisms 2021;9:1062. [PMID: 34068994 DOI: 10.3390/microorganisms9051062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang Z, Gao C, Zhang H, Yang J, Wang Y, Pan L, Yu H, He C, Luo H, Zhao Z, Zhou X, Wang Y, Fu J, Han P, Dong Y, Wang G, Li S, Wang Y, Jiang J, Zhong W. Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.032] [Reference Citation Analysis]
7 Jeffery IB, Das A, O'Herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C, Shanahan F, O'Toole PW. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology 2020;158:1016-1028.e8. [PMID: 31843589 DOI: 10.1053/j.gastro.2019.11.301] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 12.7] [Reference Citation Analysis]
8 Simpson S, Mclellan R, Wellmeyer E, Matalon F, George O. Drugs and Bugs: The Gut-Brain Axis and Substance Use Disorders. J Neuroimmune Pharmacol 2021. [PMID: 34694571 DOI: 10.1007/s11481-021-10022-7] [Reference Citation Analysis]
9 Watt KD. The evolving role of the microbiome in liver failure and liver transplantation. Liver Transpl 2016;22:58-61. [PMID: 27588961 DOI: 10.1002/lt.24623] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Średnicka P, Juszczuk-Kubiak E, Wójcicki M, Akimowicz M, Roszko MŁ. Probiotics as a biological detoxification tool of food chemical contamination: A review. Food Chem Toxicol 2021;153:112306. [PMID: 34058235 DOI: 10.1016/j.fct.2021.112306] [Reference Citation Analysis]
11 Brown JB, Langley SA, Snijders AM, Wan KH, Morris SNS, Booth BW, Fisher WW, Hammonds AS, Park S, Weiszmann R, Yu C, Kirwan JA, Weber RJM, Viant MR, Mao JH, Celniker SE. An integrated host-microbiome response to atrazine exposure mediates toxicity in Drosophila. Commun Biol 2021;4:1324. [PMID: 34819611 DOI: 10.1038/s42003-021-02847-y] [Reference Citation Analysis]
12 Chen H, Gong J, Xing K, Liu M, Ren H, Luo J. Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment. Front Med 2022;8:742394. [DOI: 10.3389/fmed.2021.742394] [Reference Citation Analysis]
13 Wang HY, Sun SD, Ni YZ, Bi YJ, Du Q. Clinical drugs for reflux esophagitis. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2988-2995 [DOI: 10.11569/wcjd.v24.i19.2988] [Reference Citation Analysis]
14 Eribo OA, du Plessis N, Ozturk M, Guler R, Walzl G, Chegou NN. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? Cell Mol Life Sci 2020;77:1497-509. [PMID: 31729564 DOI: 10.1007/s00018-019-03370-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zhang J, Chen Y, Sun Y, Wang R, Zhang J, Jia Z. Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine. Drug Deliv 2018;25:1175-81. [PMID: 29790376 DOI: 10.1080/10717544.2018.1469687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res 2017;179:204-22. [PMID: 27591027 DOI: 10.1016/j.trsl.2016.08.002] [Cited by in Crossref: 238] [Cited by in F6Publishing: 202] [Article Influence: 39.7] [Reference Citation Analysis]
17 da Silva Ferreira AR, Wardill HR, Tissing WJE, Harmsen HJM. Pitfalls and novel experimental approaches to optimize microbial interventions for chemotherapy-induced gastrointestinal mucositis. Curr Opin Support Palliat Care 2020;14:127-34. [PMID: 32324645 DOI: 10.1097/SPC.0000000000000497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Heppert JK, Davison JM, Kelly C, Mercado GP, Lickwar CR, Rawls JF. Transcriptional programmes underlying cellular identity and microbial responsiveness in the intestinal epithelium. Nat Rev Gastroenterol Hepatol 2021;18:7-23. [PMID: 33024279 DOI: 10.1038/s41575-020-00357-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Garcia WL, Miller CJ, Lomas GX, Gaither KA, Tyrrell KJ, Smith JN, Brandvold KR, Wright AT. Profiling How the Gut Microbiome Modulates Host Xenobiotic Metabolism in Response to Benzo[ a ]pyrene and 1-Nitropyrene Exposure. Chem Res Toxicol . [DOI: 10.1021/acs.chemrestox.1c00360] [Reference Citation Analysis]
20 Cheng H, Liu J, Tan Y, Feng W, Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. Journal of Pharmaceutical Analysis 2021. [DOI: 10.1016/j.jpha.2021.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Jia Q, Wang L, Zhang X, Ding Y, Li H, Yang Y, Zhang A, Li Y, Lv S, Zhang J. Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. Pharmacol Res 2020;151:104552. [PMID: 31747557 DOI: 10.1016/j.phrs.2019.104552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
22 Dey P. Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. Pharmacol Res. 2019;147:104367. [PMID: 31344423 DOI: 10.1016/j.phrs.2019.104367] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
23 Dias AM, Cordeiro G, Estevinho MM, Veiga R, Figueira L, Reina-Couto M, Magro F; the Clinical Pharmacology Unit, São João Hospital University Centre. Gut bacterial microbiome composition and statin intake-A systematic review. Pharmacol Res Perspect 2020;8:e00601. [PMID: 32476298 DOI: 10.1002/prp2.601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
24 Dempsey JL, Little M, Cui JY. Gut microbiome: An intermediary to neurotoxicity. Neurotoxicology 2019;75:41-69. [PMID: 31454513 DOI: 10.1016/j.neuro.2019.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
25 Sankaranarayanan R, Valiveti CK, Dachineni R, Kumar DR, Lick T, Bhat GJ. Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention. Mol Med Rep 2020;21:20-34. [PMID: 31746356 DOI: 10.3892/mmr.2019.10822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Haga SB. Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges. Pharmgenomics Pers Med 2019;12:273-85. [PMID: 31686893 DOI: 10.2147/PGPM.S179172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Dibattista A, Rampersaud D, Lee H, Kim M, Britz-mckibbin P. High Throughput Screening Method for Systematic Surveillance of Drugs of Abuse by Multisegment Injection–Capillary Electrophoresis–Mass Spectrometry. Anal Chem 2017;89:11853-61. [DOI: 10.1021/acs.analchem.7b03590] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
28 Holmes M, Flaminio Z, Vardhan M, Xu F, Li X, Devinsky O, Saxena D. Cross talk between drug-resistant epilepsy and the gut microbiome. Epilepsia 2020;61:2619-28. [PMID: 33140419 DOI: 10.1111/epi.16744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
29 Liu Z, Parida S, Wu S, Sears CL, Sharma D, Barman I. Label-Free Vibrational and Quantitative Phase Microscopy Reveals Remarkable Pathogen-Induced Morphomolecular Divergence in Tumor-Derived Cells. ACS Sens 2022;7:1495-505. [PMID: 35583030 DOI: 10.1021/acssensors.2c00232] [Reference Citation Analysis]
30 Xu S, Sui S, Zhang X, Pang B, Wan L, Pang D. Modulation of autophagy in human diseases strategies to foster strengths and circumvent weaknesses. Med Res Rev 2019;39:1953-99. [PMID: 30820989 DOI: 10.1002/med.21571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Khalsa J, Duffy LC, Riscuta G, Starke-reed P, Hubbard VS. Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine. Clinical Pharmacology in Drug Development 2017;6:176-85. [DOI: 10.1002/cpdd.310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
32 Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. J Intern Med 2018. [PMID: 29806961 DOI: 10.1111/joim.12780] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
33 Zhang J, Zhang J, Wang R. Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 2018;50:357-68. [PMID: 30227749 DOI: 10.1080/03602532.2018.1497647] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
34 Chen W, Qian J, Fu J, Wu T, Lv M, Jiang S, Zhang J. Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants. Front Pharmacol 2022;13:860237. [DOI: 10.3389/fphar.2022.860237] [Reference Citation Analysis]
35 Liu L, He X, Feng Y. Coronary heart disease and intestinal microbiota. Coron Artery Dis 2019;30:384-9. [PMID: 31276455 DOI: 10.1097/MCA.0000000000000758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Madan S, Mehra MR. The gut microbiome and transplantation: An amazon jungle. The Journal of Heart and Lung Transplantation 2018;37:1043-4. [DOI: 10.1016/j.healun.2018.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Feng W, Ao H, Peng C, Yan D. Gut microbiota, a new frontier to understand traditional Chinese medicines. Pharmacol Res 2019;142:176-91. [PMID: 30818043 DOI: 10.1016/j.phrs.2019.02.024] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 28.7] [Reference Citation Analysis]
38 Kuntz TM, Gilbert JA. Introducing the Microbiome into Precision Medicine. Trends in Pharmacological Sciences 2017;38:81-91. [DOI: 10.1016/j.tips.2016.10.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
39 Huang H, Wang X, Zhang X, Zhang G, Jinbo M, Wang H, Yu P, Jiang W. Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation. Cancer Chemother Pharmacol 2020;85:195-204. [DOI: 10.1007/s00280-019-03996-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ndayishimiye J, Popat A, Blaskovich M, Falconer JR. Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides. J Control Release 2020;324:728-49. [PMID: 32380201 DOI: 10.1016/j.jconrel.2020.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
41 Tang XY, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y. Human organoids in basic research and clinical applications. Signal Transduct Target Ther 2022;7:168. [PMID: 35610212 DOI: 10.1038/s41392-022-01024-9] [Reference Citation Analysis]
42 Zhou YX, Fuentes-Creollo G, Ponce F, Langley SA, Jen KY, Celniker SE, Mao JH, Snijders AM. No difference in 4-nitroquinoline induced tumorigenesis between germ-free and colonized mice. Mol Carcinog 2019;58:627-32. [PMID: 30632250 DOI: 10.1002/mc.22972] [Reference Citation Analysis]
43 Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, Zhong XB. Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 2017;7:241-8. [PMID: 28388695 DOI: 10.1016/j.apsb.2016.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
44 Vamanu E. Polyphenolic Nutraceuticals to Combat Oxidative Stress Through Microbiota Modulation. Front Pharmacol 2019;10:492. [PMID: 31130865 DOI: 10.3389/fphar.2019.00492] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
45 Boonchooduang N, Louthrenoo O, Chattipakorn N, Chattipakorn SC. Possible links between gut-microbiota and attention-deficit/hyperactivity disorders in children and adolescents. Eur J Nutr 2020;59:3391-403. [PMID: 32918136 DOI: 10.1007/s00394-020-02383-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
46 Luo K, Xing Y. Metabolic profile analysis of Zhi-zi-chi decoction in feces of normal and chronic unpredictable mild stress-induced depression rats based on UHPLC-ESI-Q-TOF-MS/MS and multiple analytical strategies. RSC Adv 2019;9:40037-50. [DOI: 10.1039/c9ra06486a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
47 Lucchetti M, Kaminska M, Oluwasegun AK, Mosig AS, Wilmes P. Emulating the gut-liver axis: Dissecting the microbiome's effect on drug metabolism using multiorgan-on-chip models. Curr Opin Endocr Metab Res 2021;18:94-101. [PMID: 34239997 DOI: 10.1016/j.coemr.2021.03.003] [Reference Citation Analysis]
48 Li CY, Cui JY. Regulation of protein-coding gene and long noncoding RNA pairs in liver of conventional and germ-free mice following oral PBDE exposure. PLoS One 2018;13:e0201387. [PMID: 30067809 DOI: 10.1371/journal.pone.0201387] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
49 Chen KF, Chan LN, Lin YS. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. J Pharmacokinet Pharmacodyn 2020;47:493-512. [PMID: 32710209 DOI: 10.1007/s10928-020-09701-4] [Reference Citation Analysis]
50 Walsh J, Gheorghe CE, Lyte JM, van de Wouw M, Boehme M, Dinan TG, Cryan JF, Griffin BT, Clarke G, Hyland NP. Gut microbiome-mediated modulation of hepatic cytochrome P450 and P-glycoprotein: impact of butyrate and fructo-oligosaccharide-inulin. J Pharm Pharmacol 2020;72:1072-81. [PMID: 32337713 DOI: 10.1111/jphp.13276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Mukherjee S, Joardar N, Sengupta S, Sinha Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings. J Nutr Biochem 2018;61:111-28. [PMID: 30196243 DOI: 10.1016/j.jnutbio.2018.07.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
52 Tarasiuk A, Fichna J. Gut microbiota: what is its place in pharmacology? Expert Review of Clinical Pharmacology 2019;12:921-30. [DOI: 10.1080/17512433.2019.1670058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
53 Rodrigues D, Rowland A. From Endogenous Compounds as Biomarkers to Plasma-Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics-Absorption, Distribution, Metabolism, Excretion-Drug-Drug Interaction Science Finally Arrived? Clin Pharmacol Ther. 2019;105:1407-1420. [PMID: 30554411 DOI: 10.1002/cpt.1328] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
54 Deng C, Deng B, Jia L, Tan H, Zhang P, Liu S, Zhang Y, Song A, Pan L. Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats. Evid Based Complement Alternat Med 2017;2017:7350251. [PMID: 28167974 DOI: 10.1155/2017/7350251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
55 Abdelsalam NA, Ramadan AT, ElRakaiby MT, Aziz RK. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. Front Pharmacol 2020;11:390. [PMID: 32372951 DOI: 10.3389/fphar.2020.00390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
56 Smith RL, Kyllesø L, Haslemo T, Andreassen OA, Molden E. Reduction in N-Desmethylclozapine Level Is Determined by Daily Dose But Not Serum Concentration of Valproic Acid-Indications of a Presystemic Interaction Mechanism. Ther Drug Monit 2019;41:503-8. [PMID: 31259880 DOI: 10.1097/FTD.0000000000000619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
57 Le Daré B, Ferron PJ, Couette A, Ribault C, Morel I, Gicquel T. In vivo and in vitro α-amanitin metabolism studies using molecular networking. Toxicol Lett 2021;346:1-6. [PMID: 33872745 DOI: 10.1016/j.toxlet.2021.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ostrov BE, Amsterdam D. Immunomodulatory interplay of the microbiome and therapy of rheumatic diseases. Immunol Invest 2017;46:769-92. [PMID: 29058546 DOI: 10.1080/08820139.2017.1373828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
59 Bishop-Freeman SC, Skirnick O, Noble CN, Eagerton DH, Winecker RE. Effects of Bariatric Surgery Observed in Postmortem Toxicology Casework. J Anal Toxicol 2019;43:651-9. [PMID: 31424074 DOI: 10.1093/jat/bkz062] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Wang G, Fu H, Ye W, Zheng X, Xiao J, Kang D, Rao T, Shao Y, Xie L, Liang Y. Comprehensive characterization of the in vitro and in vivo metabolites of ziyuglycoside I in rat microsome, intestinal flora, excretion specimen and fresh tissues based on LC–Q-TOF/MS. Journal of Pharmaceutical and Biomedical Analysis 2016;128:191-200. [DOI: 10.1016/j.jpba.2016.05.032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
61 Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci 2017;74:2959-77. [PMID: 28352996 DOI: 10.1007/s00018-017-2509-x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 26.6] [Reference Citation Analysis]
62 Witkamp RF, van Norren K. Let thy food be thy medicine….when possible. European Journal of Pharmacology 2018;836:102-14. [DOI: 10.1016/j.ejphar.2018.06.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
63 da Silva Ferreira AR, van der Aa SAJ, Wehkamp T, Wardill HR, Ten Klooster JP, Garssen J, Harthoorn LF, Hartog A, Harmsen HJM, Tissing WJE, van Bergenhenegouwen J. Development of a self-limiting model of methotrexate-induced mucositis reinforces butyrate as a potential therapy. Sci Rep 2021;11:22911. [PMID: 34824316 DOI: 10.1038/s41598-021-02308-w] [Reference Citation Analysis]
64 Nycz J, Zajdel A. Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii. Postępy Higieny i Medycyny Doświadczalnej 2021;75:762-72. [DOI: 10.2478/ahem-2021-0009] [Reference Citation Analysis]
65 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Ventura M, Meschi T. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 2017;7:11102. [PMID: 28894183 DOI: 10.1038/s41598-017-10734-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 16.6] [Reference Citation Analysis]
66 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
67 Hao DC, Yang L. Drug metabolism and disposition diversity of Ranunculales phytometabolites: a systems perspective. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1047-65. [DOI: 10.1080/17425255.2016.1201068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
68 Min S, Kim S, Cho SW. Gastrointestinal tract modeling using organoids engineered with cellular and microbiota niches. Exp Mol Med 2020;52:227-37. [PMID: 32103122 DOI: 10.1038/s12276-020-0386-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
69 Nichols RG, Zhang J, Cai J, Murray IA, Koo I, Smith PB, Perdew GH, Patterson AD. Metatranscriptomic Analysis of the Mouse Gut Microbiome Response to the Persistent Organic Pollutant 2,3,7,8-Tetrachlorodibenzofuran. Metabolites 2019;10:E1. [PMID: 31861317 DOI: 10.3390/metabo10010001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Milner E, Stevens B, An M, Lam V, Ainsworth M, Dihle P, Stearns J, Dombrowski A, Rego D, Segars K. Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases. Front Microbiol 2021;12:689958. [PMID: 34434175 DOI: 10.3389/fmicb.2021.689958] [Reference Citation Analysis]
71 Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. FASEB J 2022;36:e22350. [PMID: 35579628 DOI: 10.1096/fj.202101986R] [Reference Citation Analysis]
72 Rescigno M. The microbiota revolution: Excitement and caution. Eur J Immunol 2017;47:1406-13. [PMID: 28675439 DOI: 10.1002/eji.201646576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
73 Ma KC, Perli SD, Lu TK. Foundations and Emerging Paradigms for Computing in Living Cells. Journal of Molecular Biology 2016;428:893-915. [DOI: 10.1016/j.jmb.2016.02.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
74 Beger RD, Schmidt MA, Kaddurah-Daouk R. Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. Metabolites 2020;10:E129. [PMID: 32230776 DOI: 10.3390/metabo10040129] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
75 Brusselaers N. Prescribed Drugs and the Microbiome. Gastroenterol Clin North Am 2019;48:331-42. [PMID: 31383274 DOI: 10.1016/j.gtc.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
76 Shin W, Wu A, Massidda MW, Foster C, Thomas N, Lee DW, Koh H, Ju Y, Kim J, Kim HJ. A Robust Longitudinal Co-culture of Obligate Anaerobic Gut Microbiome With Human Intestinal Epithelium in an Anoxic-Oxic Interface-on-a-Chip. Front Bioeng Biotechnol 2019;7:13. [PMID: 30792981 DOI: 10.3389/fbioe.2019.00013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
77 Zhang X, Zhang G, Ren Y, Lan T, Li D, Tian J, Jiang W. Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo. European Journal of Pharmacology 2018;834:288-94. [DOI: 10.1016/j.ejphar.2018.07.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
78 Zhang J, Zhang J, Wang R, Jia Z. Effects of Gut Microbiota on Drug Metabolism and Guidance for Rational Drug Use Under Hypoxic Conditions at High Altitudes. Curr Drug Metab 2019;20:155-65. [PMID: 30338735 DOI: 10.2174/1389200219666181019145159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Hatton GB, Madla CM, Rabbie SC, Basit AW. All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. Int J Pharm 2018;548:408-22. [PMID: 29969711 DOI: 10.1016/j.ijpharm.2018.06.054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
80 Camelo-Castillo A, Rivera-Caravaca JM, Orenes-Piñero E, Ramírez-Macías I, Roldán V, Lip GYH, Marín F. Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. J Clin Med 2021;10:715. [PMID: 33670220 DOI: 10.3390/jcm10040715] [Reference Citation Analysis]
81 Chen F, Li D, Zhang B, Sun J, Sun F, Ji X, Qiu J, Parker RB, Laizure SC, Xu J. Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance? Drug Metabolism Reviews 2018;50:369-97. [DOI: 10.1080/03602532.2018.1497645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
82 Salter R, Beshore DC, Colletti SL, Evans L, Gong Y, Helmy R, Liu Y, Maciolek CM, Martin G, Pajkovic N, Phipps R, Small J, Steele J, de Vries R, Williams H, Martin IJ. Microbial biotransformation – an important tool for the study of drug metabolism. Xenobiotica 2019;49:877-86. [DOI: 10.1080/00498254.2018.1512018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
83 Fournier E, Roussel C, Dominicis A, Ley D, Peyron MA, Collado V, Mercier-Bonin M, Lacroix C, Alric M, Van de Wiele T, Chassard C, Etienne-Mesmin L, Blanquet-Diot S. In vitro models of gut digestion across childhood: current developments, challenges and future trends. Biotechnol Adv 2021;:107796. [PMID: 34252564 DOI: 10.1016/j.biotechadv.2021.107796] [Reference Citation Analysis]
84 Zheng S, Wang L, Xiong J, Liang G, Xu Y, Lin F. Consensus Prediction of Human Gut Microbiota-Mediated Metabolism Susceptibility for Small Molecules by Machine Learning, Structural Alerts, and Dietary Compounds-Based Average Similarity Methods. J Chem Inf Model 2022. [PMID: 35156807 DOI: 10.1021/acs.jcim.1c00948] [Reference Citation Analysis]